TRVI
$11.19
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough.
Recent News
A Look At Trevi Therapeutics (TRVI) Valuation After FDA Green Light For Phase 3 Trials
Trevi Therapeutics (TRVI) shares are in focus after the company completed its End-of-Phase 2 meeting with the U.S. Food and Drug Administration, clearing the way for two global Phase 3 trials of nalbuphine ER. See our latest analysis for Trevi Therapeutics. At a share price of US$11.01, Trevi’s 7 day share price return of 17.22% decline and 90 day share price return of 12.69% decline sit against a much stronger 1 year total shareholder return of 63.11%. This suggests that long term momentum...
Zacks.com featured highlights include Trevi, Metalla Royalty & Streaming and Vermilion
Trevi, Metalla Royalty & Streaming and Vermilion have been highlighted in this Screen of The Week article.
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March
TRVI, MTA and VET have posted strong one-year gains and now meet momentum and price-range screens that signal potential breakout opportunities in March.
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio
Trevi Therapeutics (TRVI) has drawn investor attention after a recent move in its share price, with the stock closing at $11.92 and showing mixed returns over the past week, month, and past three months. See our latest analysis for Trevi Therapeutics. That 12.03% 7 day share price return and 13.42% 30 day share price return sit against a slightly negative 90 day share price return. At the same time, the 1 year total shareholder return of 163.72% and very large 5 year total shareholder return...
Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 102.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.